About Stemline Therapeutics

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemline’s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial. Behind its lead, Stemline is developing a broad

Top 100 in Health Diagnostics in United States
Company Highlights
Year Founded

2003

icon-altStatus

Acquired

icon-altEmployees

534

Location (HQ)

USA

Since Last Funding

5 years 1 month

Monthly Website Visitors

9.0K

icon-altTotal Investment Amt

$200M

Last Funding Round

Post Ipo Equity

icon-altMoM Headcount Growth

1.33%

icon-altYoY Headcount Growth

22.47%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Health Care

Biotechnology

Biotechnology Research

Oncology

Health Diagnostics